Bingfan Du

Medicine · Health Sciences

11h-index365citations53works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(24), HER2/EGFR in Cancer Research(15), Chemical Synthesis and Analysis(12), Monoclonal and Polyclonal Antibodies Research(12), Peptidase Inhibition and Analysis(7)

Publications53 total

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2025Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Data from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Figure S1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Dorin Toader(33), Marc Damelin(33), Timothy B. Lowinger(33), Kalli C. Catcott(32), Elizabeth Ditty(31), LiuLiang Qin(30), David H. Lee(28), Stephen P. Bradley(28), Ling Xu(27), Susan M. Clardy(26), Alex Uttard(26), Jeffrey Zurita(24), Kenneth Avocetien(23), Kelly L. Lancaster(22), Tyler Carter(22), Mark Nazzaro(22), Dokyong Kim(22), Naniye Malli(21), Thomas H. Pillow(21), Neelie T. Zacharias(21)